GEN Stock Cash Flow Statements

Gen Digital Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Gen Digital Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-03-31	2018-06-30	2018-03-31	2017-09-30	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30

cash flows from operating activities
net income	-16,802,000	-95,930,000	-29,316,000	38,681,000	-17,359,000	-25,082,000	-62,857,000	-108,673,000	-615,024,000	41,314,000	-52,379,000	-35,958,000	-71,028,000	-312,640,000	-60,942,000	-34,936,000	-118,250,000	-64,000	643,000	-2,781,000	1,295,000	-3,002,000	-12,075,000	1,523,000	3,070,000	5,695,000	6,068,000	3,497,000	6,337,000	6,930,000	-232,611,000	10,571,000	11,844,000	10,841,000	-25,308,000	4,545,000	8,881,000	-161,316,000	9,053,000	8,215,000	10,867,000	10,265,000	9,576,000	8,924,000	8,444,000	7,184,000	6,864,000
adjustments to reconcile net income to net cash from operating activities:
non-cash interest and leasing arrangements	6,695,000	6,424,000	6,023,000	5,901,000	6,117,000	5,222,000	16,138,000	22,878,000	18,827,000		22,589,000	22,650,000	24,989,000	24,275,000	21,920,000	24,192,000	23,413,000
other non-cash gain	-19,834,000	-53,507,000	-44,100,000	-84,832,000	-1,364,000
share based compensation				1,894,000	1,596,000	2,087,000	2,130,000	2,427,000	2,439,000		3,579,000	1,590,000	1,590,000	620,000	1,949,000	530,000	25,373,000
depreciation and amortization expense	23,656,000	24,373,000	33,816,000	25,988,000	21,764,000	38,195,000
reduction in the carrying amount of operating lease right-of-use assets				31,506,000
recovery for losses on accounts receivable	-523,000
equity in net income of unconsolidated affiliates	-1,358,000	-3,362,000	-3,576,000	127,000					-69,000		-893,000	-497,000	-763,000		-640,000
benefit for deferred taxes	-293,000	3,051,000	-422,000	-1,331,000	1,595,000	-835,000					-25,955,000	-417,000	4,415,000
loss (income) on early extinguishment of debt
long-lived asset impairments				9,700,000	0		27,257,000	28,360,000
changes in assets and liabilities:
accounts receivable	13,347,000	6,193,000	98,650,000	7,321,000	-18,869,000	20,974,000	23,856,000	-870,000	-35,671,000		-33,305,000	-42,212,000	-60,866,000	-42,398,000	-23,531,000	-207,477,000	128,782,000	-13,268,000	-7,892,000	-7,538,000	-5,105,000	-5,968,000	12,509,000	-12,888,000	-8,149,000	-320,000	-2,172,000	-661,000	-12,140,000	2,509,000	-428,000	1,734,000	-13,114,000	-6,646,000	1,157,000	-4,984,000	-4,035,000	904,000	-1,629,000	-3,789,000	-11,322,000	-4,900,000	-5,658,000	9,607,000	-14,717,000	-14,123,000	-12,701,000
accounts payable and other accrued expenses and other	6,703,000	-19,806,000	24,374,000	7,277,000	-13,725,000	-18,759,000	-30,131,000	-10,026,000	15,069,000		4,373,000	-1,267,000	37,839,000	11,901,000	-5,277,000	-22,000,000	44,606,000
medicare advance payments
operating lease obligations	-24,891,000	-25,167,000	-27,610,000	-28,511,000	-26,999,000	-21,567,000
net cash from operating activities	34,573,000	-59,439,000	325,347,000	15,250,000	-22,924,000	12,146,000	17,556,000	-6,087,000	-1,769,000	33,059,000	11,787,000	-931,000	24,446,000	13,567,000	2,780,000			-5,138,000	10,245,000	15,477,000	5,737,000	11,089,000	23,043,000	9,308,000	4,481,000	11,740,000	16,816,000	15,142,000	-1,022,000	33,189,000	20,961,000	33,355,000	11,875,000	31,160,000	-34,373,000	20,373,000	18,138,000	29,490,000	16,631,000	20,812,000	7,964,000	20,340,000	15,967,000	24,670,000	2,036,000	16,240,000	6,547,000
cash flows from investing activities:
capital expenditures	-13,576,000	-9,944,000	-10,818,000	-21,278,000	-15,681,000	-23,529,000	-10,690,000	-16,461,000	-14,624,000	-22,328,000	-22,893,000	-21,654,000	-26,243,000	-20,230,000	-28,635,000
free cash flows	20,997,000	-69,383,000	314,529,000	-6,028,000	-38,605,000	-11,383,000	6,866,000	-22,548,000	-16,393,000	10,731,000	-11,106,000	-22,585,000	-1,797,000	-6,663,000	-25,855,000
purchases of marketable securities	-24,795,000	-18,303,000	-23,828,000	-12,359,000	-22,420,000	-14,700,000	-24,034,000	-16,009,000	-6,354,000		-3,853,000	-21,070,000	-13,922,000	-56,397,000	-5,683,000
proceeds on maturity or sale of marketable securities				19,416,000	14,449,000	8,257,000	17,383,000	15,702,000	30,998,000		6,740,000	32,809,000	13,465,000	21,611,000	2,280,000	7,265,000	10,158,000
purchases of assets				-9,146,000	0	-252,475,000									-1,895,000
sales of assets	40,878,000	10,791,000	46,437,000	161,408,000	20,174,000	79,000,000			-36,000		1,051,000				0	0	1,263,000
restricted deposits				749,000	-2,596,000						-2,253,000
investments in joint venture				-14,886,000							76,000
loan provided to joint venture	0	0	0	-9,000,000
notes receivable and other investment additions
other	1,653,000	-2,404,000	-245,000	32,000	-485,000	28,000	126,000	-1,099,000	-575,000		1,491,000	1,997,000	-366,000	484,000	1,695,000	-951,000	912,000
net cash from investing activities	12,042,000	-192,176,000	31,666,000	114,936,000	6,031,000	-203,419,000	-17,215,000	-17,867,000	6,929,000		-37,862,000	-19,293,000	58,117,000	-185,551,000	-39,066,000	-35,157,000	6,290,000	-3,738,000	-2,886,000	-1,651,000	-3,550,000	9,484,000	-3,996,000	-3,580,000	-2,401,000	-7,009,000	-5,416,000	-3,625,000	-3,475,000	-15,204,000	-18,540,000	-3,656,000	-2,517,000	-7,864,000	-4,769,000	-54,074,000	-9,698,000	-15,336,000	-11,839,000	-7,297,000	-11,696,000	-14,731,000	-19,609,000	-25,248,000	-8,789,000	-10,468,000	-59,142,000
cash flows from financing activities:
borrowings under revolving credit facilities	1,014,900,000	1,046,420,000	1,391,198,000	1,093,643,000	1,139,000,000	1,163,000,000	1,307,284,000	440,000,000
repayments under revolving credit facilities	-1,014,900,000	-1,046,420,000	-1,477,110,000	-1,143,692,000	-1,112,199,000	-1,194,676,000	-1,280,706,000	-445,749,000
proceeds from issuance of long-term debt	854,000	193,828,000	26,693,000	7,339,000	57,632,000	170,565,000	492,000	561,894,000	6,392,000		171,151,000	115,114,000	67,872,000	134,100,000	1,101,000	0	360,000,000					69,805,000				0	0
repayment of long-term debt	-24,292,000	-25,997,000	-51,838,000	-89,654,000	-65,713,000	-4,467,000	-6,255,000	-451,169,000	-10,399,000		-172,990,000	-136,216,000	-127,717,000	-6,296,000	-9,527,000
repayment of finance lease obligations				-712,000	-672,000	-575,000
debt issuance and settlement costs
contributions from noncontrolling interests	544,000				0	18,500,000
distributions to noncontrolling interests and stockholders	-2,086,000	-1,334,000	-1,164,000	-1,123,000	-1,561,000	-1,138,000	-566,000	-15,000	-1,222,000		-357,000	-300,000	-240,000
net cash from financing activities	-30,933,000	183,777,000	-113,190,000	-134,439,000	14,630,000	147,501,000			-19,314,000	-21,741,000	33,237,000	14,698,000	-91,902,000	173,856,000	12,994,000	27,659,000	4,352,000	1,969,000	-4,783,000	-10,071,000	-2,159,000	-18,991,000	-18,471,000	-8,858,000	1,066,000	-5,927,000	-13,773,000	-15,826,000	-1,639,000	-18,410,000	-994,000	-15,624,000	-12,610,000		42,185,000	31,751,000	-9,861,000	-13,861,000	-14,121,000	-8,794,000	9,138,000	-7,889,000	4,256,000	299,000	5,733,000	-1,085,000	50,587,000
net increase in cash, cash equivalents and restricted cash and equivalents	15,682,000	-67,838,000			-2,263,000	-43,772,000	20,965,000	63,469,000
cash, cash equivalents and restricted cash and equivalents:
beginning of period	0	0	0	125,806,000	0	142,276,000	0	58,638,000	0		0	0	61,543,000	0	0	0	87,548,000
end of period	15,682,000	-67,838,000	243,823,000	121,553,000	-2,263,000	98,504,000	20,965,000	122,107,000	-14,154,000		7,162,000	-5,526,000	52,204,000	1,872,000	-23,292,000	-12,745,000	95,708,000
supplemental cash flow information:
interest paid	28,890,000	25,637,000	22,900,000	31,815,000	34,832,000	45,620,000	101,438,000	91,393,000	107,328,000		109,437,000	112,616,000	111,456,000	108,134,000	107,942,000	105,139,000	94,948,000
net taxes paid				1,430,000	-1,176,000	1,081,000	1,020,000	3,084,000
federal and state stimulus - covid-19 other income
non-cash investing and financing activities:
finance lease obligations, net write-down due to lease activity	84,000	55,000			472,000
assets subject to finance lease obligations, net write-down due to lease activity	-80,000	-29,000
operating lease obligations, net (write-down) gross-up due to lease activity
assets subject to operating leases, net write-down (gross-up) due to lease activity	60,835,000	222,382,000
financing obligations, net write-down due to lease activity					0
assets subject to financing obligations, net write-down due to lease activity					0
debt issuance costs		-3,165,000	-239,000	-240,000	-1,857,000	-3,708,000	-126,000	-16,552,000	-1,735,000		-7,615,000	-2,510,000	-2,316,000	-1,417,000	-1,000
federal stimulus - covid-19 other income
provision (recovery) for losses on accounts receivable			-161,000	201,000
loss on early extinguishment of debt				1,328,000			0	9,300,000	0
net decrease in cash, cash equivalents and restricted cash and equivalents				-4,253,000
finance lease obligations, net gross up (write-down) due to lease activity				309,000
assets subject to finance lease obligations, net (gross-up) write-down due to lease activity				-310,000	1,077,764,000
operating lease obligations, net gross-up due to lease activity				-18,757,000	14,218,000	2,408,557,000
assets subject to operating leases, net (gross-up) due to lease activity				14,320,000	-9,294,000	-2,264,702,000
(recovery) benefit from losses on accounts receivable
goodwill and identifiable intangible asset impairments
gain on early extinguishment of debt
notes receivable and other investment reductions
debt settlement costs							501,000	-986,000
operating lease right-of-use asset amortization						29,574,000
benefit from losses on accounts receivable						-685,000		-1,524,000	25,187,000		25,602,000	29,681,000	26,493,000	31,692,000	23,320,000	22,117,000	23,392,000
equity in net (income) loss of unconsolidated affiliates						-61,000
(gain) loss on early extinguishment of debt
other non-cash (gains) charges						-16,917,000
finance lease obligations, net (write-down) gross-up due to lease activity						-131,842,000
assets subject to finance lease obligations, net write-down (gross-up) due to lease activity						61,512,000
financing obligations, net (write-down) gross-up due to lease activity						-2,734,940,000
assets subject to financing obligations, net write-down (gross-up) due to lease activity						1,718,507,000
customer receivership and other related charges
proceeds from tenant improvement draws under lease arrangements									0		48,000	610,000	499,000	887,000	1,938,000	0	95,000
capital lease obligations, net (write-down) gross-up due to lease activity
assets subject to capital lease obligations, net write-down (gross-up) due to lease activity
equity in net income (income) of unconsolidated affiliates							38,000	220,000
capital lease obligations and assets
financing obligations							-130,935,000	5,152,000	7,019,000		21,005,000	4,067,000	3,861,000	56,489,000	1,021,000	22,797,000	3,682,000
financing obligation assets
other non-cash charges								68,000
depreciation and amortization								51,503,000	59,390,000		61,104,000	67,953,000	61,765,000	61,576,000	62,494,000	53,616,000	60,077,000	5,994,000	6,120,000	6,035,000	6,085,000	6,226,000	6,130,000	6,047,000	6,219,000	6,276,000	6,258,000	6,591,000	6,275,000	6,193,000	6,459,000	6,432,000	6,145,000	6,806,000	6,305,000	5,992,000	5,944,000	5,950,000	6,014,000	5,867,000	5,477,000	5,444,000	5,301,000	5,073,000	5,160,000	5,068,000	4,419,000
benefit from deferred taxes								250,000	1,997,000						-13,408,000
net cash provided (used in) by financing activities								87,423,000
capital lease obligations								-18,194,000
other non-cash charges and gains									2,378,000		-5,174,000	-42,922,000	12,000	9,387,000	-3,105,000
customer receivership									298,000
net change in restricted cash and equivalents									-2,701,000		20,596,000	-8,190,000	8,578,000	22,572,000	-6,828,000
purchases of inpatient assets, net of cash acquired											-38,817,000	-68,704,000	-778,000
borrowings under revolving credit facility									127,000,000		195,000,000	243,000,000	224,000,000	275,000,000	223,000,000	220,000,000	146,500,000
repayments under revolving credit facility									-139,350,000		-152,000,000	-205,000,000	-254,000,000	-227,000,000	-201,000,000
net decrease in cash and cash equivalents											7,162,000
cash and cash equivalents:
net taxes refunded									61,000
capital leases									0		0			0	13,444,000
sale of investment in joint venture											0	0	1,010,000				26,358,000
net increase in cash and cash equivalents													-9,339,000	1,872,000
consolidated statement of operations data:
net revenues
expenses
income before income tax (benefit) expense
income tax (benefit) expense
income from continuing operations
income from discontinued operations, net of taxes
less net income (income) attributable to noncontrolling interests
net income attributable to genesis healthcare, inc.
loss per common share:
weighted-average shares used for eps calculation
basic
diluted
net income per common share attributable to genesis healthcare, inc.:
other financial data:
net cash from investing activities, net of capital expenditures
balance sheet data:
cash and cash equivalents
working capital
property and equipment and leased facility assets
total assets
long-term debt, including current installments
capital lease obligations, including current installments
financing obligations, including current installments
stockholders' (deficit) equity
net taxes (refunded) paid											4,207,000	196,000	-14,180,000
non-cash financing activities:
assumption of long-term debt														0	111,000	110,166,000	326,610,000
sales of inpatient assets													76,373,000
long-lived asset impairment
transaction costs
issuance of stock
taxes paid														1,910,000	5,314,000	7,752,000	5,917,000
sale of investment in joint ventures															0
distributions to noncontrolling interests															-2,517,000
cash and equivalents:
cash flows from operating activities:
total adjustments																	115,768,000
purchase of marketable securities
net increase in cash and equivalents																	8,160,000
supplemental disclosure of cash flow information:
deferred income taxes and other current assets																	42,533,000
property, plant and equipment																	495,692,000
change in fair value of contingent consideration																		-476,000	7,000	-121,000	14,000	-1,620,000	79,000
benefit from doubtful accounts																		3,763,000	3,737,000	3,720,000	2,905,000	5,638,000	2,661,000	3,114,000	2,983,000	2,107,000	1,740,000	1,787,000	1,775,000	2,035,000	1,037,000	1,938,000	2,457,000	2,191,000	2,232,000	2,599,000	2,595,000	2,707,000	1,648,000	4,881,000	1,803,000	3,185,000	3,377,000	2,097,000	1,428,000	2,642,000	959,000
non-cash stock-based compensation																		1,810,000	1,013,000	875,000	571,000	763,000	601,000	331,000	1,303,000	1,183,000	1,196,000	1,208,000	1,163,000	1,174,000	247,000	1,189,000	998,000	1,346,000	981,000	862,000	360,000	530,000	610,000	608,000	520,000	438,000	510,000	306,000	304,000	240,000	136,000
excess tax benefits from stock-based payment arrangements																										0	0	0	242,000	54,000	0	-14,000	-295,000									0
gain on disposal of property and equipment
amortization of deferred financing costs																		742,000	723,000	903,000	900,000	768,000	779,000	685,000	638,000	640,000	530,000	818,000	825,000	851,000	826,000	825,000	826,000	825,000	923,000	723,000	1,421,000	1,422,000	1,421,000	1,074,000	794,000	793,000	794,000	795,000	686,000	636,000	583,000
deferred income taxes																		-7,000	-899,000	-444,000	918,000	1,755,000	-6,364,000	3,603,000	477,000	2,475,000	1,384,000	-1,162,000	793,000	59,000	-21,262,000	40,000	10,077,000	3,333,000	-4,923,000	1,052,000	484,000	1,642,000	5,214,000	-779,000	-111,000	177,000	380,000	-432,000	-784,000	3,377,000	-808,000
amortization of discount on debt																		134,000	134,000	141,000	141,000	186,000	235,000	237,000	238,000	318,000	156,000	288,000	144,000	168,000
debt retirement costs																										0	168,000
impairment of long-lived assets																														0
changes in operating assets and liabilities:
payments on notes receivable																		449,000	446,000	220,000	507,000	1,009,000	885,000	642,000	777,000	817,000	817,000	739,000	743,000	-798,000	2,226,000	927,000	959,000	1,446,000	1,507,000	950,000	943,000	2,052,000	1,828,000
other current and non-current assets																		-864,000	-764,000	4,280,000	-2,276,000	-3,558,000	-1,394,000	-31,000	-1,611,000	-2,037,000	1,257,000	284,000	-1,456,000	3,837,000	-4,587,000	9,212,000	-1,007,000	1,465,000	-8,349,000	-691,000	-597,000	3,983,000	-267,000	2,111,000	3,944,000	1,635,000	-437,000	1,304,000	-393,000
accounts payable and accrued liabilities																		-585,000	7,053,000	6,969,000	-5,671,000	3,752,000	1,696,000	-1,207,000	1,973,000	-7,750,000	2,952,000	-4,027,000	-1,303,000	3,526,000	-766,000	1,215,000	-3,482,000	4,762,000	-10,082,000	4,217,000	2,799,000	4,890,000	-5,553,000	3,960,000	-5,509,000	7,108,000	-2,939,000	-5,244,000	1,998,000	18,083,000	4,218,000
employee compensation and benefits																		-3,945,000	536,000	2,430,000	3,309,000	-4,154,000	-3,330,000	4,949,000	-5,277,000	4,060,000	-1,489,000	4,121,000	-5,609,000	4,781,000	329,000	1,604,000	-5,348,000	6,369,000	2,229,000	1,462,000	-879,000	-1,850,000	-730,000	289,000	694,000	-2,092,000	2,869,000	1,930,000	-2,352,000	3,420,000	3,961,000
insurance liability risks																		943,000	-863,000	-419,000	2,231,000	809,000	2,678,000	2,065,000	2,206,000	-1,544,000	-90,000	-1,060,000	1,057,000	450,000	-884,000	-1,635,000	538,000	310,000	-2,090,000	-2,753,000	143,000	-1,783,000	-879,000	-1,939,000	667,000	-2,342,000	202,000	-193,000	1,843,000	-2,578,000	40,000
other long-term liabilities																		495,000	162,000	298,000	-87,000	1,505,000	-1,858,000	1,311,000	-366,000	-203,000	-1,983,000	-1,094,000	132,000	1,279,000	-248,000	-838,000	847,000	-146,000	2,605,000	-1,672,000	52,000	356,000	493,000	288,000	53,000	650,000	1,879,000	476,000	392,000	-10,014,000	1,109,000
cash flows from investing activities
additions to property and equipment																		-3,738,000	-2,982,000	-2,711,000	-3,550,000	-3,459,000	-3,996,000	-3,580,000	-2,401,000	-7,009,000	-5,416,000	-3,622,000	-3,475,000	-5,182,000	-4,893,000	-3,656,000	-2,567,000	-4,575,000	-4,769,000	-8,694,000	-9,698,000	-11,973,000	-10,255,000	-8,499,000	-10,428,000	-15,156,000	-13,226,000	-12,311,000	-8,933,000	-9,000,000	-7,771,000
acquisitions																										0	0
proceeds from sale of property and equipment																										0	0				0	0	400,000
proceeds from sale of investments
proceeds from the sale of home health agency																		0
proceeds from the sale of land																		0
cash flows from financing activities
borrowings under line of credit																		74,000,000	67,500,000	78,500,000	78,500,000	109,499,000	89,083,000	76,000,000	89,000,000	72,500,000	72,000,000	149,000,000	13,500,000	0	21,500,000	11,000,000	55,500,000	19,500,000	52,500,000	54,500,000	48,000,000	78,000,000	-12,000,000	2,000,000	12,000,000	-5,000,000	6,000,000	2,000,000	10,000,000		48,000,000
repayments under line of credit																		-68,000,000	-70,335,000	-85,000,000	-78,057,000	-87,942,000	-126,583,000	-77,000,000	-84,000,000	-73,000,000	-82,000,000	-103,500,000	-13,500,000	0	-21,500,000	-25,000,000	-67,500,000	-38,500,000	-8,500,000	-118,500,000	-55,000,000
repayments of long-term debt																		-3,106,000	-1,759,000	-2,654,000	-2,087,000	-107,934,000	-57,934,000	-5,391,000	-3,730,000	-4,415,000	-3,514,000	-156,307,000	-1,187,000
cash paid for financing costs
proceeds from exercise of stock options																		316,000	0
taxes paid related to net share settlement of equity awards																		-1,574,000	-3,000	-9,000	-334,000	-81,000	34,000	-18,000	-204,000	-3,000	-2,000	-19,000	-210,000	40,000	-59,000
increase in cash and cash equivalents																		-6,907,000	2,576,000	3,755,000	28,000	1,582,000	576,000	-3,130,000	3,146,000	-1,196,000	-2,373,000			-425,000	1,427,000			992,000	3,043,000	-1,950,000	-1,421,000	293,000	-8,939,000	4,721,000	5,406,000
cash and cash equivalents at beginning of period																		0	0	0	4,177,000	0	0	0	2,003,000	0	0	0	16,017,000	0	0	0	4,192,000	0	0	0	3,528,000	0	0	0	2,047,000		0	0	5,012,000		0
cash and cash equivalents at end of period																		-6,907,000	2,576,000	3,755,000	4,205,000	1,582,000	576,000	-3,130,000	5,149,000	-1,196,000	-2,373,000	-4,309,000	9,881,000	-425,000	1,427,000	14,075,000	940,000	992,000	3,043,000	-1,950,000	2,107,000	293,000	-8,939,000	4,721,000	7,453,000		614,000	-279,000	3,992,000		-2,008,000
loss on disposal of assets																			68,000
debt modification/retirement costs																			21,000				432,000
impairment of long lived assets																			0
proceeds from maturity of investments																			0
payment of financing costs																			-186,000	-1,856,000	-181,000		-2,877,000
exercise of stock options																														0	0	0	26,000
disposal of fixed assets																																			-1,708,000
acquisition of healthcare facilities and businesses, net of cash acquired																														-10,372,000
proceeds from divestitures
(gain) loss on disposal of property and equipment
cash paid for purchase of previously leased facilities
disposal of property and equipment																											24,000				0	3,000	290,000
additions to deferred financing costs																											-257,000							0	214,000			0	0				0	0	-1,383,000		-319,000
acquisition of home health licenses																															0	0	-350,000
decrease in cash and cash equivalents																													-6,136,000				-3,252,000										614,000	-279,000	-1,020,000		-2,008,000
net income from continuing operations																																		10,841,000	-25,308,000	4,545,000	8,881,000	-161,316,000
net income from discontinued operations																																						0
tax benefit from reversal of accrual for uncertain tax positions																																						-624,000
write-off of deferred financing costs																																		0	0
proceeds from sale of land
repayments of long-term debt and capital leases																														-18,396,000	-935,000	-939,000	-931,000	-3,304,000	-2,029,000	-251,128,000	-2,861,000	-2,861,000	-2,121,000	-2,842,000	-2,862,000
issuance of debt
cash flows from discontinued operations																																						0
proceeds from issuance long-term debt
amortization of discount and accretion on debt																																152,000	140,000		148,000
acquisition of healthcare facilities and businesses																																			0
(gain) loss on disposal of asset
goodwill impairment charge
acquistion of healthcare facilities and businesses
proceeds from disposal of property and equipment
fees paid for early extinguishment of debt
change in the fair value of acquisition-related contingent consideration
change in the fair value of acquistion-related contingent consideration
loss on disposal of asset																																						0	1,000	0	60,000
amortization of discount on senior subordinated notes																																					27,000	27,000	27,000	26,000	27,000	27,000	26,000	27,000	27,000	27,000	31,000
change in other assets
premium on redemption of debt and write-off of deferred financing costs
change in fair value of interest rate hedge																																														0	7,000
non-current income tax receivable
acquisition of healthcare facilities																																						-3,363,000	0			-308,000	-9,460,000			-1,210,000	-50,583,000
changes in other assets																																									-1,604,000		315,000	-14,000	-344,000	-689,000	-1,247,000
cash distributed related to the onex transaction																																														0	0
proceeds from ipo, net of expenses
supplemental cash flow information
cash paid for:
interest expense, net of capitalized interest																																								3,932,000	11,691,000		11,556,000
income taxes																																								10,051,000	572,000	2,817,000	5,436,000
non-cash activities:
conversion of accounts receivable into notes receivable																																								4,950,000	5,307,000	0	0
change in notes receivable																																									336,000
operating activities
(gain) loss on sale of assets
investing activities
financing activities
repayments on long-term debt and capital leases																																										-2,889,000	-1,767,000	-1,701,000	-2,884,000	-2,060,000	2,894,000
additions to deferred financing costs of new debt
proceeds from the issuance of new common stock
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
interest, net of capitalized interest
insurance premium financed																																										-182,000
loss on sale of assets
write-off of deferred financing costs and premium on early redemption of debt																																															0
principal payments on notes receivable
principal payments on (additions to) notes receivable																																												669,000	488,000
reorganization expenses
cumulative effect of a change in accounting principle
gain on sale of assets
forgiveness of stockholder loan
other current assets																																														2,684,000	-2,271,000
net cash paid for reorganization costs
borrowings (repayments) under line of credit
repayments on long-term debt through refinancing
redemption of preferred stock
purchase of treasury stock
proceeds from exercise of warrants and cash settlement of stock options
dividends paid
proceeds from capital contributions related to the onex transaction
proceeds from sale of interest rate hedge
purchase of interest rate hedge
supplemental disclosure of non-cash investing and financing activities:
reclassification of accounts receivable to notes receivable
loss on disposal of property and equipment
(additions to) principal payments on notes receivable
premium paid for redemption of debt																																															0
proceeds from initial public offering of common stock, net of expenses																																															12,000
(additions) principal payments on notes receivable

We provide you with 20 years of cash flow statements for Gen Digital stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Gen Digital stock. Explore the full financial landscape of Gen Digital stock with our expertly curated income statements.

The information provided in this report about Gen Digital stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.